Webinar: Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials by InsideScientific

Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials

About

Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.

Eric A. Ariazi, PhD and Terry Kelly, PhD discuss how nucleosome-based markers are poised to accelerate oncology clinical trials, offering broader applications for monitoring both toxicity and efficacy.

This session explores the critical contributions of Nu.Q® Technology to clinical epigenetics research, emphasizing its role in the identification and validation of biomarkers for epigenetic drug discovery. The technology's capability in monitoring treatment responses and its utility in elucidating the underlying mechanisms of disease processes are discussed.

Key learning objectives include:

Next-Generation Epigenetic Immunoassay for Quantitative Assessment of Circulating Nucleosomes

Pre-clinical through Clinical Development of Circulating Nucleosomes as Pharmacodynamic Biomarkers in Oncology Trials

Expanding Utility of Circulating Nucleosomes to Monitor/Predict Adverse Reactions to CAR-T cell therapy

Presenters

Eric A. Ariazi, PhD

Consultant

Eric A. Ariazi, PhD, is a distinguished Translational Medicine Scientist with 25+ years of experience spanning academia and industry. Presently, he lends his deep expertise in biomarkers for epigenetic compounds as a consultant for Volition. Dr. Ariazi’s interest in epigenetics began at Fox Chase Cancer Center where he discovered that the master transcription factor estrogen receptor-α also plays a novel role in regulating DNA methylation. Transitioning to industry, Dr. Ariazi played a pivotal role at Freenome, spearheading the development of high-depth cfDNA methylation sequencing assays for blood-based cancer detection, now key IP of the company. His tenure at ORIC Pharmaceuticals was marked by pioneering clinical biomarker strategies, notably for a PRC2 inhibitor utilizing Volition’s innovative Nu.Q™ nucleosome assays. Dr. Ariazi is an author on 31 scientific publications, including reviews and a book chapter, as well as an inventor on 4 granted patents.

Terry Kelly, PhD

Chief Innovation Officer/Chief Scientific Officer

Dr. Terry Kelly is the Chief Innovation Officer for VolitionRx and Chief Scientific Officer for Volition America. She has over 15 years of experience in epigenetics including developing novel technologies and seeing them through to commercialization. Her laboratory is based in San Diego, where they use a multi-omics approach to understand the basic epigenetic mechanisms that underly normal biology and how they are mysregulated by, and contribute to, a variety of diseases including cancer and sepsis. She received her PhD in Neuroscience from UCLA, Post-doctoral fellowship in Cancer Epigenetics from USC Norris Cancer Center and has previous leadership roles in R&D and Custom product and service development. She is an active member of the local community, including sitting on advisory boards.

First Name*

Last Name*

Email Address*

Organization / Company*

Job Title*

Country / Region*

Which area of drug development are you currently involved in?*

Have a question for Eric or Terry? Ask it here:

utm_bmcr_source